This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Genzyme

Status and phase: Completed; Phase 2

Conditions: Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

Treatments: Drug: Docetaxel; Drug: Placebo; Drug: ZD6474

Study type: Interventional

Funder types: Industry

Identifiers

NCT00047840

6474IL/0006

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologic or cytologic confirmation of NSCLC (locally advanced or metastatic, IB-IV)
• Failure of first-line platinum-based chemotherapy

Exclusion criteria

• Mixed small cell or non-small-cell histology
• Bronchoalveolar carcinoma
• Prior chemotherapy or herbal preparations must be discontinued more than 4 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin and suramin)
• Prior treatment with docetaxel

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind